60 Degrees Pharmaceuticals launches 9-month promotional pilot for ARAKODA malaria drug

60 DEGREES PHARMACEUTICALS, INC.

Nine-month pilot includes virtual sales reps and co-pay program to boost ARAKODA awareness and sales.
ARAKODA is the only FDA-approved antimalarial covering all stages of malaria, with weekly dosing.
Company plans expanded U.S. sales effort in 2025 based on pilot data.
CEO Geoffrey Dow says pilot will inform how healthcare professionals view ARAKODA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.